Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Tumor growth and metastasis heavily rely on angiogenesis, the formation of new blood vessels.
• Vascular Endothelial Growth Factor (VEGF) is a primary regulator of tumor angiogenesis.
• Targeting VEGF offers a potential therapeutic strategy against solid tumors.

Purpose of the Study:

• To investigate the efficacy of antisense phosphorothioate oligodeoxynucleotides (AS-ODNs) in blocking VEGF production.
• To evaluate the impact of VEGF inhibition on the angiogenic activity and growth of renal cell carcinoma (Caki-1) cells.
• To assess the anti-tumorigenic effects of VEGF AS-ODNs in a preclinical xenograft model.

Main Methods:

• In vitro studies using Caki-1 cells treated with VEGF AS-ODNs to assess VEGF expression, endothelial cell proliferation, and migration.
• In vivo studies involving the injection of VEGF AS-ODN treated Caki-1 cells into nude mice to evaluate angiogenic potential.
• Systemic administration of VEGF AS-ODNs to nude mice bearing Caki-1 xenografts to assess anti-tumor efficacy.

Main Results:

• In vitro treatment with VEGF AS-ODNs significantly reduced VEGF levels, impairing endothelial cell proliferation and migration in a dose-dependent and sequence-specific manner.
• In vivo, Caki-1 cells treated with VEGF AS-ODNs exhibited approximately 50% reduction in initiated vessel formation compared to controls.
• Systemic administration of VEGF AS-ODNs delayed tumor growth in mice, significantly increasing the time for xenografts to reach a target size.

Conclusions:

• Antisense inhibition of VEGF production is effective in reducing tumor angiogenesis and growth.
• VEGF AS-ODNs demonstrate preclinical efficacy against renal cell carcinoma, suggesting therapeutic potential.
• Targeting VEGF via antisense technology represents a viable strategy for anti-cancer drug development.